Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia
Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Stefan Faderl(Jazz Pharmaceuticals (United States)), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(Unknown), Farhad Ravandi‐Kashani(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Jianqin Shan(The University of Texas MD Anderson Cancer Center), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center)
Cited by 106
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k